CLINICAL TRIALS PROFILE FOR CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
✉ Email this page to a colleague
All Clinical Trials for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00160394 ↗ | Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris | Completed | GlaxoSmithKline | Phase 4 | 2004-12-01 | Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity. |
| NCT00160394 ↗ | Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris | Completed | Stiefel, a GSK Company | Phase 4 | 2004-12-01 | Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity. |
| NCT00807014 ↗ | Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne | Completed | GlaxoSmithKline | Phase 4 | 2006-11-01 | The objectives of this clinical trial are to compare the quality of life of the subjects, the efficacy and the tolerance of Duac® Gel (gel formulation with a combination of clindamycin phosphate [equivalent to 1% clindamycin] and 5% benzoyl peroxide), applied once daily, against Differin® Gel (gel with 0.1% adapalene), used once daily, in the treatment of mild to moderate acne vulgaris. |
| NCT00807014 ↗ | Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne | Completed | Stiefel, a GSK Company | Phase 4 | 2006-11-01 | The objectives of this clinical trial are to compare the quality of life of the subjects, the efficacy and the tolerance of Duac® Gel (gel formulation with a combination of clindamycin phosphate [equivalent to 1% clindamycin] and 5% benzoyl peroxide), applied once daily, against Differin® Gel (gel with 0.1% adapalene), used once daily, in the treatment of mild to moderate acne vulgaris. |
| NCT01015638 ↗ | Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications | Completed | GlaxoSmithKline | Phase 4 | 2009-08-01 | This is a single-blind (blinded expert grader) study that will enroll 25-30 healthy volunteers without facial acne. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide 5% or clindamycin phosphate and benzoyl peroxide 2.5% and the other side of the face will remain non-treated to serve as a control. |
| NCT01015638 ↗ | Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications | Completed | Stiefel, a GSK Company | Phase 4 | 2009-08-01 | This is a single-blind (blinded expert grader) study that will enroll 25-30 healthy volunteers without facial acne. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide 5% or clindamycin phosphate and benzoyl peroxide 2.5% and the other side of the face will remain non-treated to serve as a control. |
| NCT01132443 ↗ | W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzo | Completed | GlaxoSmithKline | Phase 1 | 2010-05-06 | This study was conducted to determine if the bioavailability of clindamycin and its metabolite clindamycin sulfoxide are altered by the concentration of BPO or the absence of methylparaben. This study compared the investigational study product and 2 marketed products: - CLN 1%-BPO 3% Gel (clindamycin 1%-BPO 3%), methylparaben-free - Topical Gel (clindamycin 1%-BPO 5%), methylparaben-preserved (Topical Gel-MP) - Once Daily Gel ((clindamycin 1%-BPO 5%), methylparaben-free (Topical Gel-MPF) |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
Condition Name
Clinical Trial Locations for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
Trials by Country
Clinical Trial Progress for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
Clinical Trial Phase
Clinical Trial Sponsors for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
Sponsor Name
